Guanfacine
Schizotypal Personality Disorder
Icahn School of Medicine at Mount SinaiSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Schizotypal Personality Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxytocin Maria de las Mercedes Perez Rodriguez | Phase 1 | CC |
Dar 0-100A Antonia New | Phase 2 | NR |
Same molecule, other indications
Guanfacine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →